Research compound
This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.
Nicotinamide Mononucleotide (NMN)
NAD+ precursor; early human trials suggest metabolic & energy benefits, especially in older adults.
micro:dailymicro:energymicro:longevitymicro:metabolic
Evidence last reviewed: 04 Apr 2026
Trade-offs & context
Known concerns, timing considerations, & interactions
Note
May fuel pre-existing cancer cell growth in preclinical models (NAD+ supports cell proliferation) — human significance unclear
Note
FDA has raised exclusion concerns for NMN as a dietary supplement — regulatory status is legally ambiguous in the US
Dot colour: ●High concern ●Moderate ● Low / note
Biomarkers studied
Outcomes directly measured across the evidence records below
Metabolic
Insulin Sensitivity
Performance
Muscle Endurance
Evidence
1 record
NAD+ levels / metabolic markers
Older adults; insulin-resistant individuals • RCTs (phase I/II)
PUBMEDModerate
Reliably raises blood NAD+; some improvements in insulin sensitivity & muscle endurance in older adults.
Dose: 500 mgDuration: 8–12 weeks
Human trial data growing; long-term effects unknown.
Forms
NMN powder / capsule
Sublingual may improve absorption.
Liposomal NMN
Claimed better bioavailability; limited comparative data.
Stacks containing Nicotinamide Mononucleotide (NMN)
Public community stacks that include this ingredient.
No public stacks include this ingredient yet.